Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148447
Status:
COMPLETED
Last Update Posted:
2007-05-03
First Post:
2005-09-06
Brief Title:
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
Sponsor:
BeerYaakov Mental Health Center
Organization:
BeerYaakov Mental Health Center
Study Overview
Official Title:
Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study
Detailed Description:
The aim of this study is to evaluate the therapeutic effect of escitalopram cipralex in the treatment of negative symptoms in schizophrenic patients receiving either typical or the newer atypical antipsychotics olanzapine and risperidone in a double-blind placebo-controlled study As there is no drug treatment that is considered as first-line treatment in the treatment of negative symptoms we thought that the comparison with placebo is plausible However it is important to note that the patients will receive the commonly used treatment for their disorder ie antipsychotic medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None